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Background: Aloperine, a natural alkaloid constituent isolated from the herb Sophora alopecuroides displays
anti-inflammatory properties in vitro and in vivo. Our group previously demonstrated that aloperine significantly induced
apoptosis in colon cancer SW480 and HCT116 cells. However, its specific target(s) remain to be discovered in multiple
myeloma (MM) and have not been investigated.
Methods: Human myeloma cell lines (n= 8), primary myeloma cells (n = 12), drug-resistant myeloma cell lines (n = 2), and
animal models were tested for their sensitivity to aloperine in terms of proliferation and apoptosis both in vitro and in vivo,
respectively. We also examined the functional mechanisms underlying the apoptotic pathways triggered by aloperine.
Results: Aloperine induced MM cell death in a dose- and time-dependent manner, even in the presence of the
proliferative cytokines interleukin-6 and insulin-like growth factor I. Mechanistic studies revealed that aloperine not
only activated caspase-8 and reduced the expression of FADD-like interleukin-1β-converting enzyme (FLICE)-like
inhibitory protein long (FLIPL) and FLICE-inhibitory proteins (FLIPS) but also activated caspase-9 and decreased the
expression of phosphorylated (p)-PTEN. Moreover, co-activation of the caspase-8/cellular FLICE-inhibitory protein
(cFLIP)- and caspase-9/p-PTEN/p-AKT-dependent apoptotic pathways by aloperine caused irreversible inhibition of
clonogenic survival. Aloperine induce more MM apoptosis with tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) or borterzomib. A U266 xenograft tumor model and 5T33 MM cells recapitulated the antitumor
efficacy of aloperine, and the animals displayed excellent tolerance of the drug and few adverse effects.
Conclusions: Aloperine has multifaceted antitumor effects on MM cells. Our data support the clinical
development of aloperine for MM therapy.
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Multiple myeloma (MM) is a clonal malignancy of plasma
cells that is characterized by the presence of a monoclonal
protein in the serum and/or urine, widespread osteolysis,
renal failure, and anemia [1,2]. MM survival rates, which
have historically ranged from 3 to 5 years, can now exceed
10 years due to the advent of high-dose therapy with* Correspondence: Hj164@sina.com; Zhouyi0264@126.com
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unless otherwise stated.autologous stem cell transplantation in combination with
novel chemotherapeutic agents [3,4]. However, high-dose
chemotherapy produces drug resistance in MM patients, il-
lustrating the urgent need for more effective treatments.
Current treatment approaches aim to induce apoptosis, a
form of programmed cell death responsible for tissue
homeostasis, in cancer cells [5-7]. The intrinsic apoptosis
pathway is initiated at the mitochondria, which are perme-
abilized in response to intracellular death signals, releasing
cytochrome c and other apoptotic factors into the cytosol
and activating caspase-9 and caspase-3 [8]. The extrinsic
apoptosis pathway is initiated by the binding of death re-
ceptor ligands, such as tumor necrosis factor-relatedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cognate death receptors at the cell membrane [9]. Receptor
trimerization leads to the intracellular recruitment of
adaptor proteins, such as Fas-associated death domain
(FADD), which enable the binding and activation of
caspase-8 at the death-inducing signaling complex (DISC)
[8]. Active caspase-8 activates caspase-3, resulting in apop-
tosis. As an antiapoptotic protein, cellular FLICE-inhibitory
protein (cFLIP) can block death-receptor signaling by inter-
fering with caspase-8 activation at the DISC [10].
The FADD-like interleukin-1β-converting enzyme
(FLICE)-inhibitory protein cFLIP is a death effector do-
main (DED)-containing protein that is similar to
FLICE-like inhibitory protein long (FLIPL) and FLICE-
inhibitory proteins (FLIPS). These proteins play a role
in apoptosis signaling, and cFLIP isoforms represent
critical antiapoptotic and drug resistance factors [10].
cFLIP is highly expressed in cancer cells and TRAIL-
resistant cells [11-13]. FLIP levels in TRAIL-resistant
cells are regulated by the phosphatase and tensin
homologue (PTEN)-AKT-mammalian target of rapa-
mycin (mTOR) pathway, and PTEN loss and AKT acti-
vation are correlated with increased FLIPS mRNA
translation, high levels of FLIPS expression, and TRAIL
resistance in vitro, in human glioblastoma multiforme
(GBM) xenografts and in primary human GBM sam-
ples [11].
Aloperine, a natural product identified in Sophora fla-
vescens Ait. and other Sophora plants, such as Sophora
alopecuroides [14-16], exhibits anti-inflammatory, anti-
bacterial, and antiviral properties [17,18]. Clinically, alo-
perine has been used in China to treat patients with
autoimmune diseases, such as rheumatism, lupus ery-
thematous, and eczema [19,20]. More recently, aloperine
was reported to have an antitumor effect on various can-
cers cells, including leukemia cell lines (HL-60, U937,
and K562), esophageal cancer cells (EC109), lung cancer
cells (A549), and hepatocellular carcinoma cells (HepG2)
[21]. In addition, our group previously demonstrated
that aloperine significantly induced apoptosis in colon
cancer SW480 and HCT116 cells [22,23]. Although alo-
perine induced cell cycle arrest at the G2/M phase with
concomitant increases in p21 and p53 and decreases in
cyclin D1 and B1, its specific target(s) remain to be dis-
covered; furthermore, it is not yet clear whether the drug
can also induce apoptosis in MM cells. In this study, we
demonstrate the cytotoxic effects of aloperine on pri-
mary samples and MM cell lines with or without the
protective effects of bone marrow cytokines and bone
marrow stromal cell (BMSC) adhesion. Importantly, we
determined that aloperine functions by targeting cFLIP
and phosphorylated (p)-PTEN and thus induces MM
cell apoptosis through both the intrinsic and extrinsic
apoptotic pathways, respectively.Materials and methods
Drugs, reagents, and cell lines
Aloperine (Yanchi Dushun Biological and Chemical Co.,
Ltd., Ningxia, China; Batch number: 070506; purity >99%)
and bortezomib (Millennium Pharmaceuticals) were dis-
solved in distilled water. Non-tagged TRAIL, IETD-FMK,
LEHD-FMK, and Z-VAD-FMK were obtained from
Bachem (Heidelberg, Germany). All other chemicals were
purchased from Sigma-Aldrich (China) unless otherwise
stated.
The human myeloma cell lines (OPM2, 3T3D, RPMI
8226, and NCI-H929) were kind gifts from Guangzhou
Medical University and Southern Medical University.
The dexamethasone-sensitive and dexamethasone-resistant
cell lines MM.1S and MM1.R as well as U266 cells
and the doxorubicin-resistant U266 and Dox6 cell
lines were kindly provided by Sun Yat-Sen University
Cancer Center. Cell lines were grown in RPMI 1640
(Gibco) with 10% fetal bovine serum (FBS) and 1%
penicillin and streptomycin (100 units of penicillin
and 100 μg of streptomycin).
Primary MM cells were isolated from patient bone mar-
row (the Second Affiliated Hospital in Guangzhou Medical
University) aspirates after Ficoll-Hypaque gradient centri-
fugation using CD-138-positive selection and magnetic-
assisted column sorting (Miltenyi) according to the
manufacturer’s instructions. The purity of the MM cells
was confirmed to be >90% via flow cytometric analysis
using an anti-CD138 antibody (Miltenyi). CD138-negative
mononuclear cells were also used to establish long-term
BMSC cultures, as described previously [24]. BMSCs were
obtained from MM patients and used between the third
and fifth passages for all experiments. Informed written
consent was obtained from all patients’ parents/guardians,
and the study was approved by Guangzhou Medical
University Clinical Research Ethics Committee.
To generate stable cell lines, cells were seeded in six-
well tissue culture plates and transfected with cFLIPL in
pBABE, cFLIPS in pCFG5-IEGZ, or the corresponding
empty vectors using FuGENE 6 (Roche Applied Science,
Mannheim, Germany) according to the manufacturer’s
recommendations, and clones were selected using
2.5 μg/ml puromycin or 400 μg/ml Zeocin (InvivoGen,
San Diego, CA, USA).
Cell proliferation and apoptosis assays
Cell proliferation was assessed using methanethiosulfo-
nate (MTS) assays (Promega) according to the manufac-
turer’s instructions. For co-culture experiments, cell
proliferation was measured using the BrdUrd cell prolif-
eration ELISA kit (Roche Diagnostics). MM cells were
cultured in BMSC-coated 96-well plates for 48 h with
the indicated concentrations of aloperine. Cells were
pulsed with BrdUrd during the last 8 h of the 72-h
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propidium iodide staining assay kit (R&D Systems) ac-
cording to the manufacturer’s instructions, and samples
were analyzed on a FACSCalibur (BD Biosciences) flow
cytometer.Western blotting
Western blot analyses were performed as described pre-
viously [25] using the following antibodies: caspase-8,
cFLIP, caspase-9, XIAP, Bim, caspase-3, PTEN, p-PTEN
(Ser380/Thr382/383), PARP, p-AKT (Ser-473), AKT, β-
actin, MCL-1 (all from Cell Signaling, Beverly, MA),
cIAP-2 (Epitomics, Burlingame, CA, USA), cIAP-1, sur-
vivin (both from R&D Systems), Noxa, and cFLIP (Santa
Cruz Biotechnology).RNA interference
For transient knockdown of PTEN, cells were trans-
fected with 150 pmol Stealth RNAi siRNA directed
against PTEN, cFLIP (Invitrogen), or non-targeting con-
trol siRNA (Invitrogen) using the TransMessenger trans-
fection reagent (Qiagen, Hilden, Germany).Animal models and drug treatment
SCID NOD mice (Animal Experiment Center, Southern
Medical University) were used in this study. All animals
were handled in strict accordance with good animal
practice as defined by the relevant national and local
animal welfare bodies. All animal work was approved by
the Institutional Review Board of Guangzhou Medical
University (permit number: GZMU (hu) 2011–0190) in
accordance with the guidelines for animal use of the
National Institutes of Health.
Mice were inoculated subcutaneously in the abdomen
with U266 cells (5 × 106 cells per mice) and randomized
into the following treatment and control groups (5 per
group): control (PBS), bortezomib (0.1 mg/kg, i.p., 1 dose
per 3 days), TRAIL (15 mg/kg, i.p., 1 dose per 5 days), alo-
perine (20 mg/kg, p.o., daily), aloperine + TRAIL, and alo-
perine + borterzomib. Aloperine was given 24 h prior to
TRAIL treatment because our goal was to induce the death
receptors DR4 and/or DR5 by irradiation so that successive
TRAIL treatment would enhance tumor cell apoptosis
10 days postinjection. Tumor growth was monitored every
5 days with calipers (width2 × length/2).
For the 5T33 myeloma mouse model (10 per group),
5 × 106 5T33 cells were injected intravenously into C57/
BL KaLwRij mice (Shanghai Faculty of Life Sciences) via
the tail vein. Bortezomib (0.1 mg/kg), PBS, and aloperine
(20 mg/kg) treatments were initiated 7 days after injec-
tion, and blood was collected at 0, 1, 2, 3, and 4 weeks
after injection.Measurement of the monoclonal protein IgG2b
After 1 h at room temperature, serum was obtained via
centrifugation of whole blood, and samples were stored
at −20°C until use. A specific analysis of mouse IgG2b in
the serum was performed using a commercially available
ELISA kit (IgG2b, Bethyl Laboratories).
Bone X-rays
Following tissue dissection and fixation, bones were
placed onto Kodak X-OMAT AR scientific imaging film
(Kodak, Rochester, NY) and X-rayed using a Faxitron
radiographic inspection unit (Model 8050–020; Field
Emission Corporation, Inc., McMinnville, OR). The ex-
posed films were developed using a RP X-OMAT pro-
cessor (Model M6b; Kodak). Osteolytic lesions as small
as 0.5 mm in diameter were recognized and counted as
demarcated radiolucent lesions in the bone.
Clonogenic survival assays
Colony formation assays were performed as previously de-
scribed [26]. Briefly, 10,000 MM cells were seeded in 0.33%
agar cultures. The colonies were fed with a medium in the
presence or absence of drugs. After 18 days, the plates were
imaged, and colony numbers were counted using ImageJ.
Statistical analyses
The values presented represent the mean ± SD from at
least three experiments. IC50 values for proliferation in
the presence of aloperine were calculated as the concen-
tration of drug that resulted in a 50% reduction of viable
cells compared with untreated controls using MTS or
BrdUrd assays. Comparisons between two groups were
performed using Student’s t test, and three or more
groups were compared using ANOVA. P values <0.05 or
<0.001 were considered significant.
Results
Aloperine selectively inhibits the growth of MM cell lines
and patient cells
Forty-eight hours of treatment with 0–10 mM aloperine
or 72 h with 80 μM aloperine inhibited MM cell prolif-
eration in a dose- and time-dependent manner in all cell
lines tested, including dexamethasone-resistant MM.1R
cells and doxorubicin-resistant U266 cells (Figure 1A, B,
Additional file 1: Figure S1A, B). The IC50 of aloperine
was 80–260 μM for all cell lines and primary MM cells
(Figure 1C). In addition, aloperine inhibited the growth
of primary patient MM cells obtained from 12 MM pa-
tients who relapsed after multiple previous therapies, in-
cluding bortezomib (patients 1, 2, 3), lenalidomide
(patients 4, 5, 6), and dexamethasone (patients 7, 8, 9)
and melphalan (patients 10, 11, 12). Aloperine signifi-
cantly inhibited patient MM cell proliferation (P < 0.05
for all patients; Figure 1C). As a control, aloperine did
Figure 1 Aloperine inhibits the growth of human MM cell lines and primary MM cells but not BMSCs or PBMCs. (A, B) MM cell lines
were treated with the indicated doses of aloperine or vehicle for 48 h (A) or 80 μM aloperine for 72 h (B). Proliferation was measured using MTS
assays, and IC50 values for different cell lines ranged from 80 to 260 μM. (C) MTS assays were performed on purified MM cells from 12 patients with
relapsed MM whose diseases were resistant to chemotherapy, normal PBMCs, and malignant MM-derived BMSCs; two representative cases are shown.
In all experiments, cells were treated for 48 h with graded doses of aloperine (a,bP < 0.001 versus all patient MM cells). (D) Aloperine inhibited the
proliferation of MM cells adhering to BMSCs. After BMSCs reached confluence in a 96-well plate, U266 and MM.1S cells were added and allowed to
adhere for 4 h. Aloperine was added at the indicated doses, and BrdUrd proliferation assays were performed after 48 h of co-culture. BMSCs alone and
MM cell lines alone served as controls (aP < 0.001 versus U266 and MM.1S cells). (E) Aloperine overcomes the protective effects of recombinant human
IL-6 and recombinant human IGF-I. MM.1S and U266 cells were treated for 48 h with the indicated concentrations of aloperine in the presence or
absence of rhIL-6 and rhIGF-I at the indicated doses, and MTS assays were used to measure proliferation (aP< 0.05 versus U266 and MM.1S, respectively).
Data represent the means ± SD (n= 3). The results illustrate a representative experiment (n= 3).
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mal PBMCs at this dose, indicating that its cytotoxicity
is selective to MM cells.
Aloperine overcomes the cytoprotective effects of MM
bone marrow
Next, we utilized BrdUrd incorporation assays to inves-
tigate the cytotoxicity of aloperine on MM cells with
and without adhesion to BMSCs. MM cells alone and
BMSCs alone served as the controls. BrdUrd incorpor-
ation was slightly reduced in BMSCs at doses that sig-
nificantly inhibited BrdUrd uptake in MM cells(Figure 1D). BrdUrd uptake by U266 cells was significantly
elevated by co-culture with BMSCs (2.15-fold, P = 0.000),
whereas a more modest upregulation was observed for
MM.1S cells (1.54-fold, P = 0.03), suggesting that BMSCs
promote MM cell proliferation. Similar results were ob-
served in other MM cell lines, including RPM1-8226
and OPM2 (Additional file 1: Figure S1C). However,
aloperine prevented cell proliferation in MM-BMSC co-
cultures (P = 0.06 and P = 0.052 for U266 and MM.1S,
respectively; Figure 1D). These data suggest that aloper-
ine overcomes the cytoprotective effects of the MM-
host BM microenvironment.
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IGF-I on MM cells
Because previous reports demonstrated that IL-6 and
IGF-I secretion from BMSCs confers growth, survival,
and drug resistance in MM cells [27], we next examined
whether aloperine retains its ability to trigger MM cell
death in the presence of these cytokines.
U266 and MM.1S cells were treated with different
doses of aloperine for 48 h. Neither cytokine protected
MM cells from aloperine-mediated apoptosis (Figure 1E);
however, both cytokines promoted MM cell growth
(Figure 1E). The aloperine-mediated inhibition of MM
cell proliferation was unchanged in the presence of
these cytokines (P = 0.073 and 0.084 for U266 and
MM.1S, respectively; Figure 1E). Similar results were
observed in other MM cell lines (P = 0.101 and 0.064 for
RPM1 and OPM2, respectively; Additional file 1: Figure
S1D).
Aloperine triggers dose-dependent, caspase-mediated
apoptosis
Treatment of U266 and MM.1S cells with aloperine in-
duced apoptosis in a dose-dependent manner (Figure 2A).
Next, we analyzed whether treatment with aloperine acti-
vated caspases, which are key executioners of apoptosis. To
verify the rapid caspase activation observed using the
FACSscan assay, we monitored the effects of aloperine on
different caspases using Western blot analysis. We ob-
served an obvious accumulation of cleaved caspase-8
and, to a lesser extent, cleaved caspase-9 and caspase-3
(Figure 2B). Indeed, the inhibition of caspase-8 using
the specific pharmacological inhibitor IETD-FMK sig-
nificantly decreased aloperine-induced cell apoptosis (P <
0.05, versus control), whereas the inhibition of caspase-9
(LEHD-FMK) moderately blocked aloperine-triggered
U266 cell death (P < 0.05) (Figure 2C). Moreover, incuba-
tion of U266 cells with a pan-caspase inhibitor (Z-VAD-
FMK) markedly abrogated aloperine-induced apoptosis
(Figure 2C).
Aloperine activates caspase-8 by downregulating cFLIP
Previous studies have established an antiapoptotic role
for cFLIP [28]. Our data indicate that aloperine de-
creased both FLIPL and FLIPS in a time-dependent
manner (Figure 3A). In addition, aloperine slightly up-
regulated Noxa in MM.1S cells; however, this effect was
not observed in U266 cells, and changes in the expres-
sion of BimEL and cIAP-1 were not consistent in both
cell lines (Figure 3A). Furthermore, levels of clAP-2,
XIAP, and MCL-1 were unchanged in both cell lines. In
contrast, survivin was reduced 48 h after aloperine treat-
ment in U266 cells (Figure 3A), indicating that survivin
is likely a key mediator of this sensitization. Importantly,
FLIPL and FLIPS levels were decreased in aloperine-pretreated cells, coinciding with an increase in caspase-8
cleavage fragments (Figure 2B).
To determine whether caspase-8 mediates aloperine-
induced apoptosis through cFLIP, we overexpressed both
isoforms of cFLIP (Figure 3B). Indeed, overexpression of
FLIPL or FLIPS blocked caspase-8 cleavage and signifi-
cantly decreased aloperine-induced apoptosis (Figure 3C,
D). To further test the functional relevance of the
aloperine-mediated downregulation of cFLIP, we silenced
cFLIP expression by RNA interference. Importantly,
knockdown of cFLIP significantly increased aloperine-
induced apoptosis (Additional file 1: Figure S2).
Aloperine activates caspase-9 by downregulating
phosphorylated PTEN
The PTEN-AKT pathway plays an important role in
cancer, and loss of PTEN function increases p-AKT
levels, promoting the accumulation of caspase-9 [29].
Thus, we sought to determine whether increased PTEN
in aloperine-treated cancer cells reduced the levels of p-
AKT and activated caspase-9. Figure 4A demonstrates
that aloperine induced AKT and PTEN phosphorylation.
The maximum decrease in p-AKT was observed at
60 min, whereas p-PTEN peaked at 15 min. The in-
crease in p-PTEN thus occurred earlier than that of p-
AKT, indicating that PTEN plays a key role in the
aloperine-mediated activation of PTEN-AKT. Com-
pared with caspase-9, there was less change in total
PTEN and AKT protein expression in MM cells exposed
to aloperine for 24 or 48 h (data not shown). Moreover, in-
creased p-AKT and p-PTEN were observed in a time-
dependent manner in IL-6-treated MM cells, but IL-6 did
not interfere with the aloperine-mediated decreases in p-
AKT and p-PTEN, indicating that aloperine reduces the
cytoprotective effects of IL-6 on MM cells (Figure 4A).
To further demonstrate that PTEN plays a key role in
aloperine-mediated cytotoxicity in MM cells, siRNA
against PTEN was transfected into U226 and MM.1S
cells. PTEN knockdown blocked the ability of aloperine
to reduce p-AKT and increase caspase-9 protein in
U266 cells, and aloperine-mediated apoptosis was also
inhibited compared with si-control U266 cells (Figure 4B,
C). These results suggest that blockade of the PTEN-
AKT-caspase-9 signaling pathway decreases the effect of
aloperine in cancer cells, suggesting that aloperine-
induced apoptosis is at least partly mediated by activated
caspase-9.
Aloperine-mediated inhibition of clonogenic survival
is irreversible and associated with a decrease in FLIPL
or FLIPS and p-PTEN
Aloperine inhibited clonogenic survival in U266 and
MM.1S cells in a dose-dependent (Additional file 1:
Figure S3) and irreversible manner. Cells were treated
Figure 2 Aloperine induces cell apoptosis in a dose-dependent manner. (A) U266 and MM.1S cells were treated with various concentrations
of aloperine for 48 h, harvested, and analyzed by flow cytometry. (B) Aloperine activates caspases. Western blot analysis of lysates from U266 and
MM.1S cells treated with 80 μM aloperine for the indicated durations with or without anti-caspase-8 or anti-caspase-9 antibodies. PF, full length;
CF, cleaved fragment. Blots are representative of three independent experiments. β-Actin was assessed by Western blotting. All proteins levels
were quantified densitometrically and are normalized to β-actin. (C) U266 cells were treated with 80 or 160 μM aloperine and the indicated
agents for 48 h (as described in panel (B)) in the presence or absence of biochemical inhibitors of caspase-3, caspase-8, or caspase-9, and apoptosis was
assessed using annexin V/propidium iodide staining. Data represent the mean ± SD. The results are from a representative experiment (n= 3) (a,bP< 0.001
versus no inhibitors in MM cells).
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Figure 3 Aloperine activates caspase-8 via downregulation of cFLIP. (A) U266 and MM.1S cells were treated with 80 μM aloperine for the
indicated durations. Protein expression levels of cFLIP, Noxa, Bimel, cIAP-1, cIAP-2, XIAP, survivin, Mcl-1, and β-actin were analyzed using Western blotting
after treatment for 0, 12, 24, or 48 h. (B, C) U266 cells were transfected with FLIPS, FLIPL, or the corresponding empty vectors (empty vector FLIPL: FLIPL-EV;
empty vector FLIPS: FLIPS-EV; FLIPL and FLIPS overexpression: FLIPL-OE and FLIPS-OE; WT: FLIPL, FLIPS). Expression of cFLIP and caspase-8 was verified by
Western blotting in EV and cFLIP OE U266 cells without (B) or with (C) different doses of aloperine. (D) Cells were treated with 80 or 160 μM aloperine for
48 h, and apoptosis was determined via FACS analysis of DNA fragmentation of propidium iodide-stained nuclei. Background apoptosis: FLIPL-EV: 1.5%;
FLIPS-EV: 1.4%; FLIPL: 0.9%; FLIPS: 1.3%. Data represent the mean ± SD of three independent experiments carried out in triplicate; aP< 0.05. GAPDH/β-actin
was assessed by Western blotting. All proteins levels were quantified densitometrically and normalized to GAPDH/β-actin.
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formation, followed by either drug removal and cell
culture in a drug-free medium for an additional 9 days
or incubation in a drug-containing medium for an add-
itional 9 days. Aloperine-mediated suppression of
clonal survival in U266 (Figure 5A, left on panel) and
MM.1S cells (Figure 5A, right on panel) was not revers-
ible after the removal of the drug.
As shown in Figure 5B, the cancer cell apoptotic factors,
survivin and cALP-1, were decreased 48 h after aloperine
treatment and increased upon drug removal, suggesting
that drug removal reactivated an antiapoptotic mechanism.
Interestingly, FLIPL and FLIPS levels remained low in
U266 cells (Figure 5B) and continued to decline in
MM.1S cells (data not shown) after the removal ofaloperine. Moreover, p-PTEN also remained at low levels
after drug removal. These results suggest that persistent
FLIPL or FLIPS degradation and sustained activation of
the PTEN-AKT signaling pathway after drug removal
contribute to the irreversibility of aloperine-mediated in-
hibition of clonogenic formation.
Aloperine augments the growth inhibition of MM cells
treated with TRAIL or bortezomib
TRAIL interaction with DR4 and DR5 transduces the
death receptor (extrinsic) and mitochondrial apoptosis
signaling pathways through the activation of caspase-8
and caspase-10; therefore, TRAIL is usually regarded as
a drug that treats cancer cells through cFLIP [30,31]. To
investigate whether aloperine is a feasible agent to
Figure 4 Aloperine activates caspase-9 via downregulation of p-PTEN. (A) U266 and MM.1S cells were treated with aloperine (80 μM), IL-6
(10 ng/ml), or both for the indicated times. The expression levels of p-PTEN and p-AKT were determined using Western blotting. (B) U266
cells were transiently transfected with siRNA against PTEN or non-targeting control siRNA and then treated with 80 μM aloperine for 48 h
prior to evaluating the expression of caspase-9, p-PTEN, p-AKT, and β-actin by Western blotting. (C) Transfected cells were treated with 80
or 160 μM aloperine for 48 h, and apoptosis was determined via FACS analysis of DNA fragmentation of propidium iodide-stained nuclei.
Background apoptosis: si-control, 2.3%; PTEN siRNA, 2.6%. Data represent the mean ± SD of three independent experiments carried out in
triplicate; aP < 0.001. GAPDH was assessed by Western blotting. All protein levels were quantified densitometrically and normalized to
GAPDH.
Wang et al. Journal of Hematology & Oncology  (2015) 8:26 Page 8 of 13
Figure 5 Aloperine-mediated inhibition of clonogenic survival is irreversible. (A) Cells were treated with aloperine (ALO) for 9 days to inhibit
clonogenic survival. Cells were then washed and cultured in a drug-free medium for an additional 9 days (ALO-9 days-washed) or continuously cultured in
a drug-containing medium for an additional 9 days (ALO-18 days), followed by colony staining. (B) Cells were treated by aloperine for 48 h, washed at the
indicated times and harvested for Western blotting analysis. (C) Aloperine displays a synergistic effect with TRAIL. U266 (left on panel) and MM.1S (right on
panel) cells were treated for 48 h with (red bars) or without (blue bars) aloperine, followed by the addition of the indicated concentrations of TRAIL for
48 h. Apoptosis was determined via FACS analysis of DNA fragmentation of propidium iodide-stained nuclei. Data represent the mean ± SD of at least
three independent experiments carried out at least in duplicate; aP< 0.001. GAPDH was assessed by Western blotting. All protein levels were quantified
densitometrically and normalized to GAPDH. (D) U266 and MM.1S cells were treated with 80 μM aloperine and aloperine (80 μM) + borterzomib (2.5 nM)
for 48 h, harvested, and analyzed by flow cytometry.
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toxicity of aloperine in combination with TRAIL in MM
cell lines. Figure 5C demonstrates that aloperine strongly
increases TRAIL-induced apoptosis in different cell lines
in a dose-dependent manner compared with treatment
with either drug alone (P < 0.05) for TRAIL concentra-
tions up to 30 ng/ml.
Bortezomib is by far one of most common treatments
for MM patients in the clinic. Borterzomib was regarded
as a positive control for our experiments; however, it is
unknown that aloperine induced MM apoptosis with
borterzomib. Figure 5D showed that aloperine + bortezo-
mib induced apoptosis more than aloperine only.
Aloperine suppresses human MM cell growth in vivo
Because sequential treatment of U266 cells with aloper-
ine followed by TRAIL enhanced apoptosis in a synergistic
manner in vitro, we sought to validate this treatment com-
bination in vivo. According to our in vitro data, a synergis-
tic effect of TRAIL and aloperine was observed when
TRAIL was added 24 h before aloperine. Therefore, after
tumor formation, mice were exposed to TRAIL,bortezomib, aloperine, aloperine + TRAIL, or aloperine
+ bortezomib, as described in the ‘Materials and
methods.’ Treatment of mice with bortezomib, aloper-
ine, TRAIL, aloperine + TRAIL, or aloperine + bortezo-
mib inhibited tumor growth (P < 0.05) (Figure 6A, B).
Interestingly, tumor growth was inhibited to a greater ex-
tent in response to aloperine followed by TRAIL or borte-
zomib administration or aloperine alone compared with
TRAIL alone (P < 0.05). Importantly, the inhibition of
tumor growth in the aloperine + TRAIL or aloperine + bor-
tezomib groups was significantly superior to that of aloper-
ine alone (P < 0.05), indicating that aloperine augments the
growth inhibition of MM cells treated with TRAIL or
bortezomib in vivo. Results consistent with the inhib-
ition of tumor growth were observed at the protein level
by Western blotting (Figure 6C). Toxicity was not ob-
served in the liver tissues of treated mice, as determined
by H&E staining (Additional file 1: Figure S4). More-
over, aloperine did not trigger leucopenia/neutropenia,
thrombocytopenia, or hepatic damage (Figure 6D).
These findings suggest that aloperine markedly reduces
tumor growth and is well tolerated in vivo.
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Aloperine-mediated the inhibition of MM cell growth
was repeated in 5T33 MM mice. We observed a time-
dependent increase in serum monoclonal IgG2b protein
levels in fresh marrow cells from the femurs of 5T33 MM
mice. Interesting, the level of IgG2b was significantly de-
creased by treatment with aloperine compared with PBS
(P < 0.05, Figure 6E). In addition, compared with PBS, mul-
tiple lytic lesions and diffuse osteopenia were obviously re-
duced in the aloperine- and bortezomib-treated groups, as
determined via X-ray (Additional file 1: Figure S5). Survival
of the mice in the aloperine- and bortezomib-treated
groups was higher than that in the PBS group (Figure 6F,
P < 0.05 and P < 0.05, respectively).
Discussion
In this study, we demonstrated that aloperine decreases
MM cell viability without affecting normal lymphocyte
viability, suggesting that it is a selective cytotoxic agent
against MM cells compared with normal BMSCs and
PBMCs. Furthermore, to explain why aloperine select-
ively treated MM cells, malignant MM-derived BMSCs
were added to the experiment. The bone marrow micro-
environment promotes MM proliferation and growth via
the secretion of IL-6. IL-6 is a major growth factor and
antiapoptotic cytokine for MM cells [32]; the importance
of IL-6 as an autocrine growth factor for MM cells is
widely accepted [24]. In the current experiment, aloper-
ine overcame the proliferative effects of IL-6, IGF-I, and
BMSCs, suggesting that aloperine could be efficacious in
treating MM.
Genetic heterogeneity and drug resistance are hallmarks
of MM [33,34] that explain, at least in part, differences in
the cytotoxic activity of different agents. Importantly, our
data demonstrate that aloperine displays anti-MM activity
in a panel of MM cell lines, including sensitive and resistant
cell lines, such as U266, U266 Dox6, MM.1S, and MM1.R,
as well as cytogenetically distinct MM cells. We observed
similar responses in patient-derived MM cells that were re-
sistant to anti-MM therapies such as bortezomib, lenalido-
mide, dexamethasone, or melphalan. These data indicate
that aloperine presents a special characteristic that sets it
apart from general chemotherapy drugs for MM.
Mechanistic studies indicated that the anti-MM activ-
ity of aloperine is associated with the activation of cas-
pases, cFLIP, Bim, and Noxa, among others. Notably,
aloperine triggers robust caspase-8 cleavage; however,
modest caspase-9 cleavage was also observed. These data
are consistent with our findings that biochemical inhibi-
tors of caspase-8 partly abrogate the anti-MM activity of
aloperine, suggesting that caspase-9 compensates to in-
duce MM apoptosis. Because cFLIP is structurally simi-
lar to caspase-8 and the expression of cFLIP isoforms isincreased in various types of cancer, including MM,
cFLIP represents a critical target for therapeutic inter-
vention, namely via inhibiting its transcription and post-
transcriptional modifications [35]. In this study, we
demonstrate that aloperine significantly decreases the
expression of cFLIP and activates procaspase-8 in MM
cells.
Furthermore, aloperine induced MM cell apoptosis in
MM cells overexpressing cFLIP, suggesting that cFLIP
downregulation is important for aloperine cytotoxicity.
Moreover, cFLIP overexpression conferred TRAIL resist-
ance; therefore, the aloperine-mediated sensitization to
TRAIL observed in our study is secondary to cFLIP down-
regulation. TRAIL is the leading death receptor ligand in
clinical development with selective activity against cancer
cells [36]. However, drug resistance severely hinders its effi-
cacy. Our data suggest that aloperine may not only help
overcome cFLIP-mediated TRAIL resistance but could also
enhance the ability of TRAIL to inhibit MM cell growth.
PTEN loss causes an mTOR-dependent increase in the
translation of FLIPS mRNA, increases the levels of antia-
poptotic FLIP proteins, and increases TRAIL resistance
[11]. PTEN suppresses AKT phosphorylation and acti-
vates caspase-9 to induce apoptosis in MM cells [29].
Furthermore, enhanced phosphorylation of PTEN at the
Ser380/Thr382/Thr383 cluster was recently shown to in-
activate PTEN and enhance PI3K-AKT pathway activa-
tion in adult T-cell leukemia-lymphoma (ATLL) and
other cancers [37]. Our study is the first to show that
aloperine regulates AKT and PTEN phosphorylation.
Declines in AKT and PTEN phosphorylation occurred in
a time-dependent manner when MM cells were treated
by aloperine. The decrease in p-PTEN occurred signifi-
cantly earlier than that in p-AKT and resulted in ele-
vated levels of p-AKT, thus further demonstrating that
PTEN plays a key role in the PTEN-AKT pathway. Im-
portantly, knockdown of PTEN partially rescued cells from
aloperine-mediated upregulation of caspase-9 and signifi-
cantly reduced aloperine-induced apoptosis (Figure 4C).
These data suggest that aloperine kills cancer cells via the
PTEN-AKT-caspase-9 signaling pathway.
At low drug concentrations, the ability of aloperine to in-
hibit clonogenic survival was irreversible. Moreover, the
ability of aloperine to inhibit MM survival was largely
dependent on cFLIP and the PTEN-AKT pathway. There-
fore, it is possible to use low doses of aloperine to achieve a
greater therapeutic index because normal fibroblasts are
much more resistant to the drug than MM cells are.
In addition to our in vitro studies, we also examined
the anti-MM activity of aloperine in vivo using a human
MM xenograft mouse model. To demonstrate drug ac-
tivity, bortezomib and TRAIL were included as positive
controls. Marked tumor growth inhibition was observed
following treatment with bortezomib, TRAIL, aloperine,
Figure 6 Aloperine suppresses human MM cell growth in vivo. (A) The mean ± SD of tumor volume (mm3) of each treatment group
(n = 5/group) versus time (days). Mice were treated with PBS, TRAIL, aloperine, aloperine + TRAIL/bortezomib at the indicated doses for
30 days. (B) A significant delay in tumor growth was observed in the treated mice compared with PBS-treated control mice (aP < 0.001
versus PBS). Bars represent the mean ± SD. (C) Tumor lysates from control and drug-treated mice were subjected to Western blot analysis
using anti-cFLIP, p-AKT, AKT, and p-PTEN antibodies; ALO, aloperine; Bor, bortezomib. (D) Mice were treated with the indicated drugs for
30 days, and blood samples were obtained to measure serum bilirubin, hemoglobin, and creatine levels using the Quantichrom Creatinine,
Bilirubin, and Hemoglobin Assay kit (BioAssay Systems). Aloperine cured 5T33 multiple myeloma mice. 5T33 MM mice were treated with
aloperine and bortezomib for 40–45 days. E: IgG2b expression in aloperine- and bortezomib-treated mice was measured using ELISA assays.
aP < 0.001 versus PBS; bP < 0.001 versus bortezomib; cP < 0.05 versus TRAIL; dP < 0.05 versus aloperine. (F) Kaplan-Meier plots of mice treated
with the indicated concentrations of PBS, aloperine, or bortezomib. Survival was significantly increased in aloperine- and bortezomib-treated mice
compared with the untreated group (PBS). aP< 0.05 for the PBS group. aP< 0.001 versus the PBS group. Values represent the mean ± SD.
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ment with PBS alone. Interestingly, the combination of
aloperine and TRAIL/borterzomib showed a synergistic
inhibitory effect on MM growth compared with TRAIL
or aloperine alone.
5T33 models have been considered as suitable models
for human MM [38]. This murine model of human
myeloma bone disease includes radiologic evidence of
osteolysis, hypercalcemia, and increased osteoclastic
bone resorption associated with monoclonal gammopa-
thy [39]. This animal model of human myeloma bone
disease can be applied to determine the efficacy of po-
tential therapeutic agents. The 5T33 model that we uti-
lized is a systemic model of aggressive MM with the
unambiguous endpoint of hind limb paralysis [40]. In
our study, aloperine not only reduced the expression of
IgG2b and bone lesions in 5T33 mice but also increased
survival. Importantly, aloperine treatment was not toxic,
as no differences in creatinine, hemoglobin, or bilirubin
were noted. Therefore, these findings demonstrate that
aloperine elicits a dual effect in MM tumors, increases
apoptosis, and decreases proliferation.
Additional file
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